Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Could Repeat Genentech Success With Foundation Medicine Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.

You may also be interested in...



Roche Pushes Personalization With $2.4Bn Foundation Buy-Out

By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.

Roche Pushes Personalization With $2.4bn Foundation Buy-Out

By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future. 

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS077762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel